Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + oxaliplatin + S-1 + toripalimab
- Development stage
- Unknown
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Docetaxel + oxaliplatin + S-1 + toripalimab (the 'DOS + toripalimab' regimen) is a combination chemo-immunotherapy regimen currently under investigation in the **RESOLVE-2** phase II/III clinical trial. This multi-drug protocol is designed for the neoadjuvant and adjuvant treatment of patients with locally advanced, HER2-negative gastric or gastroesophageal junction adenocarcinoma. The regimen integrates three cytotoxic chemotherapy agents—**docetaxel** (a taxane microtubule stabilizer), **oxaliplatin** (a platinum-based DNA crosslinking agent), and **S-1** (an oral fluoropyrimidine prodrug)—with **toripalimab**, a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor. By combining standard-of-care chemotherapy (DOS) with immune checkpoint inhibition, the regimen aims to enhance anti-tumor immune responses and improve surgical outcomes in patients with high-risk gastric cancers.
- Other names
- DOS-Tdocetaxel, oxaliplatin, S-1, and toripalimab
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on docetaxel + oxaliplatin + S-1 + toripalimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + oxaliplatin + S-1 + toripalimab.